- Home
- AES vs CORT Comparison
AES vs CORT Comparison
Compare AES & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AES
- CORT
- Stock Information
- Founded
- AES 1981
- CORT 1998
- Country
- AES United States
- CORT United States
- Employees
- AES N/A
- CORT N/A
- Industry
- AES Electric Utilities: Central
- CORT Biotechnology: Pharmaceutical Preparations
- Sector
- AES Utilities
- CORT Health Care
- Exchange
- AES Nasdaq
- CORT Nasdaq
- Market Cap
- AES 7.1B
- CORT 8.1B
- IPO Year
- AES 1991
- CORT N/A
- Fundamental
- Price
- AES $10.41
- CORT $71.38
- Analyst Decision
- AES Hold
- CORT Strong Buy
- Analyst Count
- AES 8
- CORT 4
- Target Price
- AES $12.71
- CORT $142.00
- AVG Volume (30 Days)
- AES 16.4M
- CORT 1.4M
- Earning Date
- AES 07-31-2025
- CORT 07-28-2025
- Dividend Yield
- AES 6.71%
- CORT N/A
- EPS Growth
- AES 146.43
- CORT 8.36
- EPS
- AES 1.83
- CORT 1.14
- Revenue
- AES $12,119,000,000.00
- CORT $685,446,000.00
- Revenue This Year
- AES $3.95
- CORT $35.85
- Revenue Next Year
- AES $2.93
- CORT $35.22
- P/E Ratio
- AES $5.74
- CORT $62.59
- Revenue Growth
- AES N/A
- CORT 30.93
- 52 Week Low
- AES $9.46
- CORT $28.10
- 52 Week High
- AES $20.30
- CORT $117.33
- Technical
- Relative Strength Index (RSI)
- AES 44.02
- CORT 48.38
- Support Level
- AES $10.40
- CORT $69.60
- Resistance Level
- AES $11.73
- CORT $73.13
- Average True Range (ATR)
- AES 0.42
- CORT 3.50
- MACD
- AES -0.02
- CORT -0.18
- Stochastic Oscillator
- AES 25.02
- CORT 24.77
About AES The AES Corporation
AES is a global power company that operates in 15 countries. Its generation portfolio as of year-end 2023 totals over 35 gigawatts, including renewable energy (53%), gas (27%), coal (18%), and oil (2%). AES has majority ownership and operates six electric utilities distributing power to more than 2.5 million customers.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.